Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06915025 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
A Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Imunon.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 7
- Study locations
NCT06915025: Recruiting Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Imunon.
NCT06915025 is a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer that is actively recruiting participants, run by Imunon. The registered enrollment target is 500 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (31% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06915025, a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, is actively recruiting participants, sponsored by Imunon.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.
Primary Outcome
Overall Survival is defined as the time (in months) from the date of randomization to the date of death by any cause.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Olaparib
- DRUG Paclitaxel
- DRUG Niraparib
- DRUG IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
Study Locations (7)
Florida
- Advent Health - Orlando
Missouri
- Washington University School of Medicine in St. Louis - St Louis
Oregon
- Providence Cancer Institute - Portland
South Dakota
- Sanford Health - Sioux Falls
Tennessee
- Erlanger Health - Chattanooga
Washington
- Providence Sacred Heart Medical Center & Children's Hospital - Spokane
Wisconsin
- Froedtert and The Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2032-10-31 |
| Phase | Phase 3 |
What NCT06915025 shows while recruiting
NCT06915025 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (31% lower).
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT06915025 lists 7 locations in 7 states (Florida, Missouri, Oregon).
Frequently Asked Questions
What is clinical trial NCT06915025 about?
NCT06915025 is a clinical study titled "Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer". This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.
What is the current status of trial NCT06915025?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2025-07-09. Estimated completion is 2032-10-31.
What conditions does trial NCT06915025 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma.
What interventions are being tested in trial NCT06915025?
The interventions under investigation include: Carboplatin (DRUG), Olaparib (DRUG), Paclitaxel (DRUG), Niraparib (DRUG), IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) (DRUG).
Who is sponsoring clinical trial NCT06915025?
This trial is sponsored by Imunon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06915025 being conducted?
This trial has 7 study locations across Florida, Missouri, Oregon, South Dakota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06915025's enrollment target sits among peer trials
500 49th of 322 higher than 274 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI